tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Nov 3;107159.
doi: 10.1016/j.intimp.2020.107159. Online ahead of print.
Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis
Xiaopeng Yang[SUP] 1 [/SUP], Shasha Tian[SUP] 1 [/SUP], Hui Guo[SUP] 2 [/SUP]
Affiliations
Abstract
Purpose: Reported rates of acute kidney injury (AKI) have varied significantly among studies of coronavirus disease 2019 (COVID-19) published to date. The present meta-analysis was conducted to gain clarity regarding AKI incidence and renal replacement therapy (RRT) use in COVID-19 patients.
Methods: The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for COVID-19-related case reports published through 25 July 2020. Pooled analyses were conducted using R.
Results: The pooled incidence of AKI in 51 studies including 21,531 patients was 12.3% (95% CI 9.5-15.6%), with higher rates of 38.9% in 290 transplant patients (95% CI 27.3-51.9%), 39.0% in 565 ICU patients (95% CI 23.2-57.6%) and 42.0% among 1745 deceased patients (95% CI 30.3-54.7%). RRT usage was reported in 39 studies of 17,664 patients, with an overall pooled use of 5.4% (95% CI 4.0-7.1%), with higher rates of 15.6% in 117 transplant patients (95%CI 9.9-23.8%) and 16.3% in 776 ICU patients (95% CI 11.1-23.3%).
Conclusion: AKI and RRT use among COVID-19 patients represent a major public health concern, and early and appropriate intervention should be called upon to improve the prognosis of patients suffering from AKI.
Keywords: Acute kidney injury; COVID-19; Renal replacement therapy.
. 2020 Nov 3;107159.
doi: 10.1016/j.intimp.2020.107159. Online ahead of print.
Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis
Xiaopeng Yang[SUP] 1 [/SUP], Shasha Tian[SUP] 1 [/SUP], Hui Guo[SUP] 2 [/SUP]
Affiliations
- PMID: 33223467
- DOI: 10.1016/j.intimp.2020.107159
Abstract
Purpose: Reported rates of acute kidney injury (AKI) have varied significantly among studies of coronavirus disease 2019 (COVID-19) published to date. The present meta-analysis was conducted to gain clarity regarding AKI incidence and renal replacement therapy (RRT) use in COVID-19 patients.
Methods: The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for COVID-19-related case reports published through 25 July 2020. Pooled analyses were conducted using R.
Results: The pooled incidence of AKI in 51 studies including 21,531 patients was 12.3% (95% CI 9.5-15.6%), with higher rates of 38.9% in 290 transplant patients (95% CI 27.3-51.9%), 39.0% in 565 ICU patients (95% CI 23.2-57.6%) and 42.0% among 1745 deceased patients (95% CI 30.3-54.7%). RRT usage was reported in 39 studies of 17,664 patients, with an overall pooled use of 5.4% (95% CI 4.0-7.1%), with higher rates of 15.6% in 117 transplant patients (95%CI 9.9-23.8%) and 16.3% in 776 ICU patients (95% CI 11.1-23.3%).
Conclusion: AKI and RRT use among COVID-19 patients represent a major public health concern, and early and appropriate intervention should be called upon to improve the prognosis of patients suffering from AKI.
Keywords: Acute kidney injury; COVID-19; Renal replacement therapy.